A collaborative study between the IDIBAPS - Hospital Clínic of Barcelona and the Hospital del Mar de Barcelona permits to establish a predictive factor in the resistance to chemotherapy in breast cancer and to establish possible therapeutic targets for the improvement of this treatment. This study has been published this month in the journal Endocrine-Related Cancer and is the result of the work initiated by Dr. Albanell’s Group in Hospital Clínic, and finished in Hospital del Mar, where he leads the Unit of Oncology since almost a year. From the beginning, this study had the participation of the Unit of Pathology and Oncology of Hospital del Mar, and the Unit of Research on Cancer Experimental Therapeutics of Hospital del Mar-IMIM.
